Special Project in Non-Metastatic Castrate Resistant Prostate Cancer Review Panel

A panel of experts has been assembled to review the applications submitted to this competition.
 
Jim Hu, Chair New York Presbyterian Weill Cornell Medicine
New York, NY, USA
Scott Gilbert Moffitt Cancer Center
Tampa, FL, USA
Paul Nguyen Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School
Boston, MA, USA
Ganesh Palapattu University of Michigan
Ann Arbor, MI, USA
Steve Zeliadt University of Washington
Seattle, WA, USA
Brian Rossnagel, Community Representative Saskatoon, SK
Note: This list will be updated as panel members are recruited.




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Rocco Rossi to wrap up successful 5-year tenure as Prostate Cancer Canada CEO

September 7, 2017 - TORONTO, ON - With mixed emotions, longstanding Prostate Cancer Canada (PCC) President and CEO, Rocco Rossi, formally announced today that his time leading the organization will officially come to a close as of December 31, 2017.
More

Mutation in prostate tumours shown to change epigenetic identity, the make-up of DNA

(TORONTO, Canada - Aug 7, 2017) -- Prostate cancer researchers have mapped the impact of an acquired mutation that alters epigenetic identity, the make-up of DNA, in about 50% of patient tumour samples.
More

Movember Foundation and Prostate Cancer Canada team up to turn research into results

July 26, 2017 - TORONTO, ON - Continuing their longstanding tradition of partnering to fund high quality Canadian prostate cancer research, Prostate Cancer Canada (PCC) and The Movember Foundation today announced two new projects with very real potential to make a tangible difference in the lives of men living with aggressive forms of prostate cancer.
More


Click here for news archive